Lilly

4Q Revenues: $5.2 billion (flat)

4Q Loss: $3.6 billion (earnings were $854.4 million in 4Q07)

FY Revenues: $20.4 billion (+9%)

FY Loss: $2.0 billion (earnings were $3.0 billion FY08)

Comments: Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve sales collectively grew 10% to $1.9 billion and accounted for 37% of total sales, compared with 33% in 4Q07. Cymbalta sales were $721.2 million (+15%). Humalog sales were $457.9 million (+11%). Alimta sales were $318.7 million (+31%). Cialis sales for the quarter were $368.8 million (+7%). Zyprexa sales were down 10% to $1.1 billion. In 4Q08, the company completed the acquisition of ImClone Systems for approximately $6.5 billion and recorded pre-tax charges of $4.7 billion for in-process R&D. The company also recognized a charge of $80.0 million for asset impairments, restructuring and other special charges.